文献速递艾滋病与性传播感染

强化抗逆转录病毒治疗改善HIV相关神经认知障碍:Neuro+3研究

Improvement of HIV-associated neurocognitive disorders after antiretroviral therapy intensification: the Neuro+3 study.
PubMed 文献 · J Antimicrob Chemother · 2021-01-01

48和96周后全局缺陷评分(GDS)中位数从1.4降至1.0(P=0.009),神经认知分类显著改善(P=0.001),且GDS改善与强化后CPE≥9、CD4升高及血浆CXCL10下降相关。

要点

  • 强化抗病毒治疗提高CPE评分可显著改善HIV相关神经认知障碍。
  • GDS改善与强化后CPE≥9、CD4升高和血浆CXCL10下降独立相关。
  • 换用两类药物者认知改善更常见,提示更好控制中枢免疫激活。

核心结论

  • 在HIV相关神经认知障碍患者中,以提高CPE评分为目标的抗病毒治疗强化策略可带来显著认知改善。

研究设计与样本

  • 认知改善采用Frascati三级分类和全局缺陷评分(GDS)在强化后48周和96周评估。
  • 在基线、第48周和第96周检测血浆和脑脊液中的超敏HIV-RNA、新蝶呤、sCD14、CCL2、CXCL10、IL6、IL8和NF-L。

主要发现

  • 强化抗病毒治疗后CPE评分中位数(IQR)从基线6(4-7)升至10(9-11)。
  • 从基线至第96周,GDS中位数(IQR)从1.4(0.8-2.2)降至1.0(0.6-2.0)(P=0.009)。
  • HAND分类改善:HIV相关痴呆从2例降至1例,轻度神经认知障碍从22例降至8例,无症状神经认知损害从7例增至17例,无神经认知改变者从0例增至5例(P=0.001)。
  • 多变量线性回归显示,第96周GDS改善与强化后CPE评分≥9(P=0.014)、第48周CD4淋巴细胞升高(P<0.001)和第96周血浆CXCL10下降(P=0.001)显著相关。

临床怎么用

  • 对接受有效抗病毒治疗但仍存在HAND的患者,可考虑以提高CPE评分为目标的强化方案。
  • 强化后CPE评分≥9、CD4升高和血浆CXCL10下降可能提示认知改善机会更大。
  • 换用两类药物可能有助于更好控制中枢神经系统HIV免疫激活。

局限性

  • 原文未报告对照组,无法排除非治疗因素对认知改善的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Despite the effectiveness of antiretroviral (ARV) therapy to control HIV infection, HIV-associated neurocognitive disorders (HAND) remain frequent. The Neuro+3 study assessed the cognitive improvement associated with ARV intensification based on increased CNS penetration effectiveness (CPE) scoring ≥+3 and total CPE score ≥9. METHODS: Thirty-one patients, aged 18-65 years, with confirmed diagnosis of HAND and effective ARV therapy were included. The cognitive improvement was measured using Frascati three-stage classification and global deficit score (GDS) after 48 and 96 weeks of ARV intensification. Ultrasensitive HIV-RNA, neopterin, soluble CD14, CCL2, CXCL10, IL6, IL8 and NF-L were measured in plasma and cerebrospinal fluid at Day 0 (baseline), Week 48 (W48) and W96. RESULTS: The intensified ARV was associated with a median (IQR) CPE score increase from 6 (4-7) at baseline to 10 (9-11). From baseline to W96, the median (IQR) GDS decreased from 1.4 (0.8-2.2) to 1.0 (0.6-2.0) (P = 0.009); HAND classification improved from 2 to 1 HIV-associated dementia, 22 to 8 mild neurocognitive disorders, 7 to 17 asymptomatic neurocognitive impairment and 0 to 5 patients without any neurocognitive alterations (P = 0.001). In multivariable linear regression analysis, GDS improvement at W96 was significantly associated with CPE score ≥9 after intensification (P = 0.014), CD4 lymphocyte increase at W48 (P < 0.001) and plasma CXCL10 decrease at W96 (P = 0.001). CONCLUSIONS: In patients with HAND, a significant cognitive improvement was observed after the ARV intensification strategy, with a higher CPE score. Cognitive improvement was more often observed in the case of a switch of two drug classes, arguing for better control of CNS HIV immune activation.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Force G, Ghout I, Ropers J, et al. Improvement of HIV-associated neurocognitive disorders after antiretroviral therapy intensification: the Neuro+3 study. J Antimicrob Chemother. 2021. PMID: 33179033. doi:10.1093/jac/dkaa473

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。